Clinical Trials Logo

Nasopharyngeal Neoplasms clinical trials

View clinical trials related to Nasopharyngeal Neoplasms.

Filter by:

NCT ID: NCT04430179 Recruiting - Clinical trials for Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score >=10 at baseline.

NCT ID: NCT04340024 Recruiting - Prostate Cancer Clinical Trials

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Start date: September 30, 2015
Phase:
Study type: Observational

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

NCT ID: NCT04296851 Recruiting - Clinical trials for Familial Adenomatous Polyposis

Niclosamide for Familial Adenomatous Polyposis

Start date: February 14, 2020
Phase: Phase 2
Study type: Interventional

Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and cancers. The non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in FAP patients. However, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. Niclosamide, an anti-helminthic drug, has recently been suggested to have a suppressive effect on tumorigenesis via inhibition of Wnt pathway, and have no significant safety issues. The investigators devised a double-blind randomized controlled trial to evaluate the effect of niclosamide on polyps of colorectum and duodenum in FAP patients.

NCT ID: NCT03942380 Recruiting - Clinical trials for Head and Neck Cancer

Cell-free Tumor DNA in Head and Neck Cancer Patients

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.

NCT ID: NCT03847532 Recruiting - Clinical trials for MutYH-associated Polyposis

MUTYH-associated Polyposis

MAP
Start date: October 10, 2018
Phase: N/A
Study type: Interventional

This is single-center, prospective, non-randomized study

NCT ID: NCT03837808 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Start date: April 11, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.

NCT ID: NCT03701451 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma

Start date: February 28, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The study is to observe the efficacy and toxicity of demethylating drug decitabine and cisplatin induced chemotherapy for 3 cycles followed by concurrent chemoradiotherapy in the treatment of regionally advanced nasopharyngeal carcinoma,followed up for 2 years, observing the 2-year survival rate and variation of degrees of methylation before and after treatment,providing clinical basis for the clinical study of stage II-III.

NCT ID: NCT03666221 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Start date: November 1, 2014
Phase: Phase 2
Study type: Interventional

The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.

NCT ID: NCT03657017 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Start date: June 1, 2018
Phase: N/A
Study type: Interventional

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

NCT ID: NCT03647527 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy

Start date: September 1, 2016
Phase:
Study type: Observational

Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, single center, and exploratory study. Two contour methods of oral mucosal will be used in this study. All detail information will be recorded prospectively. The aim of this study is to explore predictive factors of acute radiotherapy induced oral mucositis in nasopharyngeal carcinoma patients treated with new precise radiotherapy (intensity modulated radiotherapy or tomography radiotherapy) by using different dosimetric parameters and clinically relevant variables.